Miled Bourourou

Miled Bourourou

Auto-generated profile, based on publicly available information

Miled Bourourou

Laboratory of Cerebrovascular Research, Montreal Neurological Institute McGill University Montreal Quebec Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
NBNicolas Blondeau
Nicolas Blondeau
RLRobert H. Lipsky
Robert H. Lipsky
MBMiled Bourourou
Miled Bourourou
MDMark W. Duncan
Mark W. Duncan
PGPhilip B. Gorelick
Philip B. Gorelick
AMAnn M. Marini
Ann M. Marini
Alpha-linolenic acid (ALA) is plant-based essential omega-3 polyunsaturated fatty acids that must be obtained through the diet. This could explain in part why the severe deficiency in omega-3 intake pointed by numerous epidemiologic studies may increase the brain’s vulnerability representing an important risk factor in the development and/or deterioration of certain cardio- and neuropathologies. The roles of ALA in neurological disorders remain unclear, especially in stroke that is a leading cause of death. We and others have identified ALA as a potential nutraceutical to protect the brain from stroke, characterized by its pleiotropic effects in neuroprotection, vasodilation of brain arteries, and neuroplasticity. This review highlights how chronic administration of ALA protects against rodent models of hypoxic-ischemic injury and exerts an anti-depressant-like activity, effects that likely involve multiple mechanisms in brain, and may be applied in stroke prevention. One major effect may be through an increase in mature brain-derived neurotrophic factor (BDNF), a widely expressed protein in brain that plays critical roles in neuronal maintenance, and learning and memory. Understanding the precise roles of ALA in neurological disorders will provide the underpinnings for the development of new therapies for patients and families who could be devastated by these disorders.

1 March 2019 in Autonomic Neuroscience
Verified
Journal Article
Closed access
CLClotilde Lecrux
Clotilde Lecrux
MBMiled Bourourou
Miled Bourourou
EHEdith Hamel
Edith Hamel

1 January 2013 in PharmaNutrition
Verified
Journal Article
Closed access
CNCarine Nguemeni
Carine Nguemeni
EGElsa Gouix
Elsa Gouix
MBMiled Bourourou
Miled Bourourou
CHCatherine Heurteaux
Catherine Heurteaux
NBNicolas Blondeau
Nicolas Blondeau

1 September 2016 in Neuropharmacology
Verified
Journal Article
Open access
MBMiled Bourourou
Miled Bourourou
CHCatherine Heurteaux
Catherine Heurteaux
NBNicolas Blondeau
Nicolas Blondeau
Stroke is a leading cause of disability and death worldwide. Numerous therapeutics applied acutely after stroke have failed to improve long-term clinical outcomes. An emerging direction is nutritional intervention with omega-3 polyunsaturated fatty acids acting as disease-modifying factors and targeting post-stroke disabilities. Our previous studies demonstrated that the omega-3 precursor, alpha-linolenic acid (ALA) administrated by injections or dietary supplementation reduces stroke damage by direct neuroprotection, and triggering brain artery vasodilatation and neuroplasticity. Successful translation of putative therapies will depend on demonstration of robust efficacy on common deficits resulting from stroke like loss of motor control and memory/learning. This study evaluated the value of ALA as adjunctive therapy for stroke recovery by comparing whether oral or intravenous supplementation of ALA best support recovery from ischemia. Motor and cognitive deficits were assessed using rotarod, pole and Morris water maze tests. ALA supplementation in diet was better than intravenous treatment in improving motor coordination, but this improvement was not due to a neuroprotective effect since infarct size was not reduced. Both types of ALA supplementation improved spatial learning and memory after stroke. This cognitive improvement correlated with higher survival of hippocampal neurons. These results support clinical investigation establishing therapeutic plans using ALA supplementation.


10 February 2022 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MLMaría Lacalle‐Aurioles
María Lacalle‐Aurioles
LTLianne J. Trigiani
Lianne J. Trigiani
MBMiled Bourourou
Miled Bourourou
CLClotilde Lecrux
Clotilde Lecrux
EHEdith Hamel
Edith Hamel
Background and Purpose: Inward rectifier potassium (KIR) channels are key effectors of vasodilatation in neurovascular coupling (NVC). KIRchannels expressed in cerebral endothelial cells (ECs) have been confirmed as essential modulators of NVC. Alzheimer's disease (AD) and cerebrovascular disease (CVD) impact on EC‐KIRchannel function, but whether oxidative stress or inflammation explains this impairment remains elusive.Experimental Approach: We evaluated KIRchannel function in intact and EC‐denuded pial arteries of wild‐type (WT) and transgenic mice overexpressing a mutated form of the human amyloid precursor protein (APP mice, recapitulating amyloid β‐induced oxidative stress seen in AD) or a constitutively active form of TGF‐β1 (TGF mice, recapitulating inflammation seen in cerebrovascular pathology). The benefits of antioxidant (catalase) or anti‐inflammatory (indomethacin) drugs also were investigated. Vascular and neuronal components of NVC were assessed in vivo.Key Results: Our findings show that (i) KIRchannel‐mediated maximal vasodilatation in APP and TGF mice reaches only 37% and 10%, respectively, of the response seen in WT mice; (ii) KIRchannel dysfunction results from KIR2.1 subunit impairment; (iii) about 50% of K+‐induced artery dilatation is mediated by EC‐KIRchannels; (iv) oxidative stress and inflammation impair KIRchannel function, which can be restored by antioxidant and anti‐inflammatory drugs; and (v) inflammation induces KIR2.1 overexpression and impairs NVC in TGF mice.Conclusion and Implications: Therapies targeting both oxidative stress and inflammation are necessary for full recovery of KIR2.1 channel function in cerebrovascular pathology caused by AD and CVD.